Celltrion   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Incheon Korea, Republic of (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2010
NCT01084863
First Marketed Drug
2002
famotidine (pepcid)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Celltrion | CELLTRION | Celltrion Inc. | Celltrion, Inc. | CELLTRION, Inc. | CELLTRION INC

Active Ingredients

Marketed Drugs (24)

clobazam (onfi) (2020)

clopidogrel (plavix) (2012)

deferasirox (exjade) (2021)

famotidine (pepcid) (2001)

fluoxetine (prozac) (2008)

infliximab (remicade) (2016)

lamivudine (epivir) (2018)

lamotrigine (lamictal) (2009)

levofloxacin (levaquin) (2011)

linezolid (zyvox) (2019)

memantine (namenda) (2015)

pioglitazone (actos) (2012)

pregabalin (lyrica) (2020)

risperidone (risperdal) (2008)

rituximab (rituxan) (2018)

rizatriptan (maxalt) (2013)

ropinirole (Requip) (2008)

sodium chloride (2011)

solifenacin (vesicare) (2019)

telmisartan (micardis) (2014)

tenofovir (viread) (2018)

trastuzumab (herceptin) (2018)

valproic acid (depakene) (2008)

zonisamide (Zonegran) (2005)

Drugs in Phase 4 Trials (4)

azathioprine (imuran) (1 trial)

infliximab (remicade) (13 trials)

methotrexate (2 trials)

thiopurine (1 trial)

Drugs in Phase 3 Trials (10)

adalimumab (humira) (4 trials)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (2 trials)

ct-p59 (3 trials)

denosumab (prolia) (2 trials)

omalizumab (xolair) (2 trials)

paclitaxel (taxol) (2 trials)

rituximab (rituxan) (8 trials)

trastuzumab (herceptin) (5 trials)

ustekinumab (stelara) (2 trials)

Drugs in Phase 2 Trials (5)

capecitabine (xeloda) (1 trial)

cisplatin (platinol) (1 trial)

ct-p27 (2 trials)

cytarabine (cytosar-u) (1 trial)

lenalidomide (revlimid) (1 trial)

Drugs in Phase 1 Trials (8)

azilsartan (edarbi) (1 trial)

ct-g11 (1 trial)

ct-g20 (1 trial)

ct-p63 (1 trial)

folic acid (1 trial)

naltrexone (revia) (1 trial)

olmesartan (benicar) (1 trial)

rosuvastatin (crestor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Breast Neoplasms (Phase 3)

Cardiomyopathies (Phase 1)

Cardiomyopathy, Hypertrophic (Phase 1)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Coronavirus Infections (Phase 3)

Crohn Disease (Phase 3)

Hypertrophy (Phase 1)

Infections (Phase 3)

Influenza, Human (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Psoriasis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Spondylitis (Phase 1)

Spondylitis, Ankylosing (Phase 1)

Stomach Neoplasms (Phase 2)

Ulcer (Phase 4)

Urticaria (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 50
  • # of Trial APIs: 27